comparemela.com
  1. Home
  2. Live Updates
  3. Japan Innovation Fund - Breaking News

Page 2 - Japan Innovation Fund News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Orasis Pharmaceuticals Submits New Drug Application for Investigational Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia

/PRNewswire/ Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing a unique eye drop to improve near vision for people.

Amy phillipsElad kedarJapan innovation fundDrug administrationSequoia capitalPrnewswire orasis pharmaceuticalsOrasis pharmaceuticalsNew drug applicationChief executive officerVisionary venturesInnovation fundBluestem capitalLifesci venture partnersMaverick ventures israel

Orasis Pharmaceuticals Announces Positive Phase 3 Topline Results of Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia

/PRNewswire/ Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing a unique eye drop to improve near vision for people.

Amy phillipsJapan innovation fundDrug administrationSequoia capitalOrasis pharmaceuticalsPrnewswire orasis pharmaceuticalsNew drug applicationVisionary venturesInnovation fundBluestem capitalLifesci venture partnersMaverick ventures israel

Orasis Pharmaceuticals Announces Positive Phase 3 Topline Results of Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia

/PRNewswire/ Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing a unique eye drop to improve near vision for people.

Amy phillipsJapan innovation fundDrug administrationSequoia capitalOrasis pharmaceuticalsPrnewswire orasis pharmaceuticalsNew drug applicationVisionary venturesInnovation fundBluestem capitalLifesci venture partnersMaverick ventures israel

Orasis Pharmaceuticals Announces Positive Phase 3 Topline Results of Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia

Orasis Pharmaceuticals Announces Positive Phase 3 Topline Results of Novel Eye Drop Candidate, CSF-1, for the Treatment of Presbyopia - read this article along with other careers information, tips and advice on BioSpace

Amy phillipsJapan innovation fundDrug administrationSequoia capitalOrasis pharmaceuticalsPrnewswire orasis pharmaceuticalsNew drug applicationVisionary venturesInnovation fundBluestem capitalLifesci venture partnersMaverick ventures israel

Orasis Pharmaceuticals to Present New Data on Novel Presbyopia Candidate at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

/PRNewswire/ Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing a unique eye drop to improve near vision for people.

United statesTel avivAmy phillipsMarjan faridPreeyak guptaElad kedarAmerican society for cataractJapan innovation fundSequoia capitalOrasis pharmaceuticalsPrnewswire orasis pharmaceuticalsRefractive surgeryAnnual meetingChief executive officerOrasis pharmaceuticalNew treatments

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.